Inhibition of the KCa3.1 channel alleviates established pulmonary fibrosisin a large animal model

Louise Organ, Barbara Bacci, Emmanuel Koumoundouros, Wayne G Kimpton, Chrishan S Samuel, Cameron J Nowell, Peter Bradding, Katy M Roach, Glen Westall, Jade Jaffar, Kenneth J Snibson

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis is a chronic progressive disease of increasing prevalence marked by poor prognosis and limited treatment options. Ca2+-activated KCa3.1 potassium channels have been shown to play a key role in the aberrant activation and responses to injury in both epithelial cells and fibroblasts, both considered key drivers in the fibrotic process of IPF. Pharmacological inhibition of IPF-derived fibroblasts is able to somewhat prevent TGF-β and bFGF-dependent profibrotic responses. In the current study, we investigated whether blockade of the KCa3.1 ion channel in-vivo with a selective inhibitor, Senicapoc, was able to attenuate both histological and physiological outcomes of early fibrosis in our large animal (sheep) model for pulmonary fibrosis. We also determined whether treatment was targeting the pro-fibrotic activity of sheep lung fibroblasts. Senicapoc was administered in established fibrosis, at 2 weeks after bleomycin instillation, and drug efficacy was assessed 4 weeks after treatment. Treatment with Senicapoc improved pre-established bleomycin-induced changes compared to vehicle control, leading to improved lung compliance, reduced extracellular matrix and collagen deposition, and a reduction in both alpha smooth muscle actin expression and proliferating cells, both in-vivo and in-vitro. These studies show that inhibiting the KCa3.1 ion channel is able to attenuate the early fibrogenic phase of bleomycin-dependent fibrosis and inhibits pro-fibrotic behaviour of primary sheep lung fibroblasts. This supports the previous research conducted in human IPF-derived fibroblasts and suggests that inhibiting KCa3.1 signalling may provide a novel therapeutic approach for IPF.
Original languageEnglish
Pages (from-to)539-550
Number of pages13
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume56
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Cite this